Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAMS-TB
NCT01785186Phase 2Completed
- Start
- Apr 2013
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of SQ109 in pulmonary tuberculosis (TB) (5 arms). Primary endpoint: Time to Sputum Culture Conversion (2 Negative Cultures) Using Liquid Media at 12 weeks. Started Apr 2013; status: completed.
02
Drugs
SQ109
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT01785186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01785186.